The infant formula shortage of 2022 was precipitated by the U.S. Food and Drug Administration’s (FDA’s) delayed response to whistleblower complaints about contaminated product—a delay caused by the agency not having the necessary policies and procedures in place to address the issue at the time—according to a new report published by the U.S. Department of Health and Human Services’ Office of the Inspector General (DHHS’ OIG).